ProSomnus Inc OSAa leader in the medical device industry for the treatment of obstructive sleep apnea, released its unaudited results for the quarter and full year ended December 31, 2022.

What happened: The company said Wednesday it expects 2022 sales to grow over 35% year over year from 2021 and also to surpass 187,500 devices prescribed by healthcare providers.

ProSomnus noted in its statement that it has launched several growth initiatives, including expanding its direct sales team in the US and Europe, commercializing its next-generation sensor device, moving to a new manufacturing facility, and developing marketing and medical programs.

The company also announced the enrollment of its first patient in the severe obstructive sleep apnea (SOS) study and full enrollment in the first-line study in the treatment of obstructive sleep apnea (FLOSAT).

“We are extremely pleased with the progress made by the ProSomnus team in 2022 across all business areas including commercialization, manufacturing, new product development and clinical data generation.” Len Lipaksaid ProSomnus co-founder and CEO in a statement Wednesday.

These results are subject to revision until the company releases its full financial results in late March. The company said it has made significant strides in treating OSA and is poised for continued growth in the future.

“As we enter the next phase of growth, we remain strongly focused on executing our global growth strategy and making precision oral devices a mainstay in the treatment and management of obstructive sleep apnea for millions of patients worldwide,” Liptak said in the statement.

Continue reading: Federal Reserve cuts to 0.25%: The pace of central bank rate hikes slows with inflation

Photo: Shutterstock